(AOF) – Nicox (+ 14.69% to 0.53 euro) posted one of the strongest increases in the SRD market after having made public a market study according to which its product NCX 470, in development for the reduction of intraocular pressure in glaucoma patients, could see annual global net sales of at least $300 million within eight years of commercial launches in the United States and China. The biotech specializing in ophthalmology specifies that it is seeking commercial partnerships in the United States and Japan for this product.
Nicox adds that NCX 470 is protected worldwide by patents covering composition of matter until 2029, with a potential extension of the term of protection of up to 5 years in the United States and Europe, and by patents covering on formulation through 2039 in the United States, Europe, Japan and China and other territories.
AOF – LEARN MORE
Find out more about the “pharmacy” sector
Loss of speed in European research
European research is losing ground to American and Chinese research. In twenty years, Europe’s share has fallen from 41% to 31% in global R&D. China’s share jumped from 1% to 8%. As for the United States, which supplanted Europe, in 2001 it devoted only 2 billion euros per year more than Europe to R&D, whereas now this gap has reached 25 billion! Some experts accuse the European authorities of not having deployed effective policies. The financing of pharmaceutical research should therefore have been better targeted via the “Horizon 2020” programme. France only comes in eighteenth position in European funding despite the quality of its research. Conversely, the United States concentrates funding on Boston and a few centers of excellence.